Terminated PHASE2 INTERVENTIONAL NCT00157508

Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy

A Pilot, Randomised, Double-blind, Cross-over Study to Assess the Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy

Sponsor: Mario Negri Institute for Pharmacological Research

Conditions Early Nephropathy Type 2 Diabetes

Interventions nitroaspirin

Updated 5 times since 2017 Last updated: Apr 8, 2015 Started: Mar 31, 2003 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Mario Negri Institute for Pharmacological Research

See all terminations from Mario Negri Institute for Pharmacological Research

Listed as NCT00157508, this PHASE2 trial focuses on Early Nephropathy and Type 2 Diabetes and remains terminated or withdrawn. Sponsored by Mario Negri Institute for Pharmacological Research, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mario Negri Institute for Pharmacological Research

Data source: Mario Negri Institute for Pharmacological Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ranica, Italy